An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial
A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine.
The World Health Organization estimates that between 127 and 300 million people around the world experience chronic migraine, defined as 15 or more headaches per month for at least three months. The disease can be debilitating and although a number of interventions exist, many only work for a certain time before they fail to prevent or relieve pain.
“This therapeutic approach offers new hope for people whose migraines cannot be treated with existing medicine,” says Stephen D. Silberstein, M.D., principal investigator of the HALO CM trial, Professor of Neurology and Director of the Jefferson Headache Center at the Vicki & Jack Farber Institute for Neuroscience at Thomas Jefferson University Hospital. “Our worldwide effort to evaluate this novel therapeutic approach has shown positive results and was safe in patients.”
Fremanezumab, a monocolonal antibody developed by Teva Pharmaceuticals, is a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP). Mounting evidence of its importance in migraines has made CGRP a focal point of research and drug development. The peptide is released at high levels during migraine in response to inflammation, and triggers a cascade effect that stimulates more CGRP release. This results in increasing sensitivity of the brain to pain. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches.
Researchers from 132 sites across nine countries enrolled 1130 patients and randomly assigned them to one of three groups: one that received quarterly treatments, a group that received one treatment per month, and one that received placebo injections. The trial lasted for 16 weeks, with a 12-week treatment window.
The results of the trial show that treatment with fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. “We saw some patients with 100 percent reduction in migraine, others with 75 percent reduction,” says Dr. Silberstein. The level of response varied between patients.
The researchers also looked at how well the therapy worked relative to each patient’s headache burden. They calculated the percent of patients who had more than a 50 percent reduction in the number of days they experienced either a severe or moderate headache per month. Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.
The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.
“If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient’s migraine load, and potentially help patients return to normal” says Dr. Silberstein.
Learn more: Phase III Immunotherapy Trial for Migraine Shows Positive Results
The Latest on: Migraines
[google_news title=”” keyword=”migraines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Woman's Shocking Experience Sparks Debate About 'Sexism in Healthcare'on April 23, 2024 at 7:12 am
A woman has sparked a conversation on social media after revealing the shocking conversation she had with a neurologist, which she claims highlights the "sexism in healthcare." Licensed psychologist ...
- Top 8 Best CBD Oils for Migraines in 2024on April 22, 2024 at 4:59 pm
Migraines have the capacity to debilitate an individual, profoundly affecting all facets of their life. The burden of pain, queasiness, as well as heightened sensitivity to light and sound can ...
- From Simon Cowell’s red-tinted glasses to ‘game-changing’ new drug – your ultimate guide to migraines & how to zap themon April 22, 2024 at 12:54 pm
CELEBRITIES go for some bold looks at times – and Simon Cowell is no exception. But when the music and TV mogul returned to our screens on Saturday night’s Britain’s Got Talent sporting red-tinted ...
- Migraine sufferers in England may soon be able to access preventative drug – here’s how atogepant workson April 22, 2024 at 8:59 am
Atogepant is the only once-daily oral CGRP receptor antagonist available for preventing and treating both episodic and chronic migraine. This offers more choice to people with migraine when it comes ...
- Britain's Got Talent's Simon Cowell reveals secret health battle that flares up during filmingon April 20, 2024 at 12:00 pm
Britain's Got Talent's Simon Cowell reveals secret health battle that flares up during filming - The ITV judge reveals he has resorted to wearing red lens glasses to help ...
- ‘30 years of migraines have robbed me of a normal life. Finally, there’s hope’on April 19, 2024 at 12:00 am
Hearing that the first oral treatment for preventing migraines could soon be available on the NHS has given me hope for a better future ...
- How migraines, flu and heart attacks affect women and men differentlyon April 16, 2024 at 9:11 am
We are all created equal, of course. But one medical truth we can’t avoid is that the sex we’re born with can determine the way we experience certain illnesses. In fact, a growing body of research is ...
- A third of women experience migraines associated with menstruation, most commonly when premenopausalon April 16, 2024 at 5:37 am
A third of the nearly 20 million women who participated in a national health survey reports migraines during menstruation, and of them, 11.8 million, or 52.5%, were premenopausal.
- Top 8 Best B2 Supplements for Migraines in 2024on April 15, 2024 at 5:00 pm
People globally struggle with migraines, a debilitating health issue. Stress, diet, and environmental elements may be potential migraine triggers, but some research indicates that a shortage of ...
- A third of women with migraines report onset during menstruationon April 15, 2024 at 8:16 am
Among U.S. women with migraine, a third say the attacks tend to coincide with their periods, a new survey finds.
via Google News and Bing News